<DOC>
	<DOCNO>NCT00210444</DOCNO>
	<brief_summary>To evaluate effect heal rate two different prognostic factor patient treat Dysport® anal fissure : duration fissure dose study drug</brief_summary>
	<brief_title>Efficacy Study Dysport® Treatment Anal Fissure .</brief_title>
	<detailed_description />
	<mesh_term>Fissure Ano</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients idiopathic anal fissure posterior anal midline Patients anal fissure present le 6 month Patients symptom ( pain ) present minimum 2 week respond 2 week standard therapy ( diet , laxative , sitzbathes ) Patients anal fistula anal fissure various cause Crohn disease , Behcet infectious ulceration , anal suppuration , subfissural infiltration , abscess , acute haemorrhoidal attack inflammatory bowel disease Patients idiopathic anal fissure anterior anal midline Patients lateral multiple fissure Patients anal perianal cancer Patients underwent previous anal surgery cicatricial alteration postsurgical cicatricial lesion Patients receive drug affect neuromuscular transmission Patients receive topical anaesthetic within 3 day injection Patients receive local treatment myorelaxing agent Patients receive prohibited analgesic Patients bleed disturbance currently use coumarin derivates Patients myasthenia genetic muscle disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>